Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Scripts Update for Week Ending 04/01
Last Short Week, numbers going in parallel with previous years
Next Week numbers will reflect a full week
V
TRx: 30,956 {vs 29,216; +5.96%} Sector +5.39%
NRx: 11,273 {vs 10,055; +12.11%} Sector +10.39%
Ref: 19,683 {vs 19,161; +2.72%} Sector +2.74%
GenL
TRx: 51,477 {vs 48,946; +5.17%}
NRx: 18,703 {vs 17,076; +9.53%}
L
TRx: 880 {vs 889; -1.01%}
NRx: 291 {vs 287; +1.39%}
V TRx Market Share: 37.16% vs 36.96% -- 4th ATH
V NRx Market Share: 37.25% vs 36.67% -- 7th ATH
V Ref Market Share: 37.11% vs 37.11% --- Equal to ATH
Deal-making in the global health-care sector is set to rebound in 2019, law firm says
https://www.cnbc.com/2019/01/07/health-care-sector-ma-set-to-rebound-in-2019-law-firm-says.html
Scripts Update for Week Ending 28/12
Short Week, numbers going in parallel with previous years
As mentioned before, Next week reading will be a tiny bit positive compared to the numbers below, and in 2 weeks’ time, back to new ATH without looking back
V
TRx: 29,216 {vs 34,470; -15.24%} Sector -13.75%
NRx: 10,055 {vs 14,891; -32.48%} Sector -28.78%
Ref: 19,161 {vs 19,579; -2.13%} Sector -2.85%
GenL
TRx: 48,946 {vs 56,166; -12.85%}
NRx: 17,076 {vs 23,252; -26.56%}
L
TRx: 889 {vs 1,014; -12.33%}
NRx: 287 {vs 357; -19.61%}
V TRx Market Share: 36.96% vs 37.61% -- 4th ATH
V NRx Market Share: 36.67% vs 38.68% -- 7th ATH
V Ref Market Share: 37.11% vs 36.84% --- ATH
Bristol-Myers to buy Celgene in a $74 billion deal
https://www.cnbc.com/2019/01/03/bristol-myers-to-buy-celgene-in-a-74-billion-deal.html
Scripts Update for Week Ending 21/12
2nd ATH Across the Board in TRx, NRx Numbers // ATH in TRx & Refills Market Share, 2nd ATH in NRx Market Share
V
TRx: 34,470 {vs 34,463; +0.02%} Sector -0.82% -- 2nd ATH
NRx: 14,891 {vs 14,600; +1.99%} Sector +1.36% -- 2nd ATH
Ref: 19,579 {vs 19,863; -1.43%} Sector -2.34% -- 4th ATH
GenL
TRx: 56,166 {vs 56,915; -1.32%}
NRx: 23,252 {vs 23,010; +1.05%}
L
TRx: 1,014 {vs 1,033; -1.84%}
NRx: 357 {vs 375; -4.80%}
V TRx Market Share: 37.61% vs 37.29% --- ATH
V NRx Market Share: 38.68% vs 38.44% -- 2nd ATH
V Ref Market Share: 36.84% vs 36.50% --- ATH
Amarin (AMRN) Stock Will Rise Again When the Dust Settles, Says Analyst
https://www.smarteranalyst.com/analyst-insights/amarin-amrn-stock-will-rise-dust-settles-says-analyst/
In early November, fish oil drug maker Amarin (AMRN) presented data called REDUCE-IT at the American Heart Association scientific sessions for a medication called Vascepa. The presentation made a splash. Doctors overwhelmingly said they would prescribe it, but some others suggested the results were over-exaggerated. Then, in December, the European Medicines Agency deemed Omega-3 fatty acids (a major component of fish oil) to be ineffective in helping those with cardiac issues, which negatively affected AMRN, even though the drug is not even available in Europe.
All the news and drama aside, Jefferies’ analyst Michael Yee says AMRN is one of the few “de-risked” standalone blockbuster drugs in the small to mid-sized market. The analyst reiterates a Buy rating with a price target of $30, showing a 56% potential upside. (To watch Yee’s track record, click here)
Yee explains that AMRN represents one of few wholly-owned, global company with multi-billion dollar potential products, which already has an FDA approval for its drug: “Given pullback from highs of $23 and down to $15 as broader equity markets fall, we think AMRN will bounce and go back up on 2019 catalyst path from scripts and sales ramp to FDA approval and/or wild-card M&A takeout…the more de-risked nature also theoretically gives less downside in volatile markets,” the analyst explains.
However, Yee does examine the bear case. “That said, from Street perspective we acknowledge significant debate from various investor discussions, but creating opportunity over 2019-20 from current $15, financing overhang removed, etc. Bears think Q4 and ’19 consensus too high, no takeout until patent settlements, risk around FDA review/delay/approval issues, new uncertainty around EMA view of fish oils (EMA might pull old inferior Omacor/Lovaza from EU market in Q1) and ultimately AZN competitor readout in 2020 and these pot’l impacts to M&A. We think consensus a little unclear (possibly stale) and may need to sort out but much of Street seems to understand this and fundamentally, scripts keep going up (see inside) as new 400-person salesforce already has called 25k docs and gearing up for 2019 […],” Yee explains.
Yee also gives some insight as to what he sees coming up on the horizon for this company– which is a pre-announcement of the fourth-quarter revenues along with 2019 opex, an FDA filing in the first quarter and an update on new manufacturer contracts extending capacity beyond the current $1 billion (just to name a few).
How does Yee’s bullish bet measure up against the word of the Street? Quite on point, it seems, considering TipRanks analytics exhibit AMRN as a Strong Buy. Out of 5 analysts polled in the last 3 months, all 5 are bullish on Amarin stock. With a return potential of over 160%, the stock’s consensus target price stands at $34.80.
Scripts: Historically this week numbers goes in parallel with readings of previous years.
If this will follow the numbers of past years, we should all expect 3 more readings of negative script increase due to short weeks, doctors on vacation, patients on vacation, holidays.....etc
The numbers that will be posted on Jan 18, 2019 for the week ending Jan 11, 2019 will be the new ATH numbers and it will pick up from there without looking back
Regards to all
Scripts Update for Week Ending 14/12
2nd ATH Across the Board in TRx, NRx & Refills Numbers
ATH in TRx & Refills Market Share, 2nd ATH in NRx Market Share
V
TRx: 34,463 {vs 35,142; -1.93%} Sector -2.01% -- 2nd ATH
NRx: 14,600 {vs 15,133; -3.52%} Sector -2.38% -- 2nd ATH
Ref: 19,863 {vs 20,009; -0.73%} Sector -1.75% -- 2nd ATH
GenL
TRx: 56,915 {vs 58,060; -1.97%}
NRx: 23,010 {vs 23,394; -1.64%}
L
TRx: 1,033 {vs 1,106; -6.60%}
NRx: 375 {vs 384; -2.34%}
V TRx Market Share: 37.29% vs 37.26% --- ATH
V NRx Market Share: 38.44% vs 38.89% -- 2nd ATH
V Ref Market Share: 36.50% vs 36.12% --- ATH
Analyst Defends Amarin (AMRN) Stock as EU Regulators Say Omega 3 is Ineffective
Amarin (AMRN) stock tumbled nearly 5% yesterday after European regulators deemed all Omega-3 fatty acid pills/medicines in Europe ineffective in preventing cardiovascular events. A research conducted by the European Medicines Agency (EMA) resulted in a statement from the department saying the European Society of Cardiology Congress found no benefit to Omega-3 supplements when it comes to cardiology. Moreover, the authority has forbidden Omega-3 fatty acid capsules from having labels suggesting it is effective in preventing cardiovascular events.
How does that affect the fish oil drug maker’s stock? Cantor analyst Louise Chen says she sees no reason for stock weakness and ultimately reiterates an Overweight rating with a price target of $35, which shows about 136% upside. (To watch Chen’s track record, click here)
Chen presents several reasons why this ruling should not affect Vascepa:
Vascepa is not commercially available in Europe and was not a part of the EMA review of effectiveness with mixture drugs in the omega-3 class, so it did not include REDUCE-IT data (An Amarin presentation sharing data showing Vascepa reduces cardiovascular events by 25%) which we think has clearly demonstrated that Vascepa reduced CV events in at-risk patients.
Also, the EMA review seems to have been conducted in follow-up to the results of the ASCEND study and other reports from earlier in 2018, all of which showed that omega-3 mixtures did not demonstrate significant cardioprotective effects. Vascepa is not an Omega-3 mixture. Icosapent ethyl is Vascepa’s unique single active ingredient.
If anything, if the EMA’s decision leads to future removal of omega-3 mixtures from the EU market, we believe that could provide upside to Vascepa’s ex-U.S. opportunity.
AMRN remains on track to submit a sNDA to expand its labeling for REDUCE-IT in early 2019, with approval expected in late 2019.
Overall, Wall Streets is rooting for AMRN to be a winning stock pick, as TipRanks analytics showcase AMRN as a Strong Buy. Based on 5 analysts polled in the last 3 months, all 5 are bullish on the stock. The 12-month average price target stands at $34.80, marking about 135% upside from where the stock is currently trading.
November-2018 vs. November-2017 (Retail + Inst. Data)
V
TRx: 144,728 {vs 119,321; +21.29%} -- Sector +7.40% --- ATH
NRx: 57,035 {vs 41,593; +37.12%} – Sector +15.21% -- ATH
Ref: 87,693 {vs 77,728; +12.82%} – Sector +3.32% -- 2nd ATH
Gen L
TRx: 266,595 {vs 251,066; +6.18%}
NRx: 95,259 {vs 84,253; +13.06%}
L
TRx: 6,566 {vs 18,687; -64.86%}
NRx: 1,507 {vs 7,645; -80.28%}
V November-2018 Retail+Inst. TRx Market Share: 34.63% vs 30.67% in November-2017 – ATH
V November -2018 Retail+Inst. NRx Market Share: 37.08% vs 31.16% in November -2017 -- ATH
V November -2018 Retail+Inst. Refill Market Share: 33.21% vs 30.41% in November -2017 – ATH
Total Monthly Retail + Institutional Data November-2018
ATH Across the board in Market Share & TRx – NRx Numbers – 2nd ATH in Refills
V
TRx: 144,728 {vs 144,697; +0.02%} -- Sector -3.36% --- ATH
(Inst # 7,458 vs 6,987; +6.74% -- Inst Sec +0.65 % -- Inst Mkt Sh 20.06% vs 18.91%)
NRx: 57,035 {vs 56,930; +0.18%} – Sector -4.26% --- ATH
Ref: 87,693 {vs 87,767; -0.08%} – Sector -2.82% -- 2nd ATH
Gen L
TRx: 266,595 {vs 280,801; -5.06%}
(Inst # 27,495 vs 27,691; -0.71%)
NRx: 95,259 {vs 102,070; -6.67%}
L
TRx: 6,566 {vs 6,902; -4.87%}
(Inst # 2,226 vs 2,262; -1.59%)
NRx: 1,507 {vs 1,650; -8.67%}
V Monthly Retail + Inst. TRx Market Share: 34.63% vs 33.46% -- ATH
V Monthly Retail + Inst. NRx Market Share: 37.08% vs 35.44% -- ATH
V Monthly Retail + Inst. Ref Market Share: 33.21% vs 32.30% -- ATH
Scripts Update Tomorrow
Sorry all, I won't be able to post the scripts number tomorrow as I'm not at the office
Monday morning will post them
Voted
Done
Total Monthly Retail ONLY Data November-2018
ATH Across the Board in Market Share
ATH in NRx Numbers, 2nd ATH in TRx & Refills Numbers
V
TRx: 137,270 {vs 137,710; -0.32%} – Sector -3.73% -- 2nd ATH
NRx: 57,035 {vs 56,930; +0.18%} – Sector -4.26% -- ATH
Ref: 80,235 {vs 80,780; -0.67%} – Sector -3.36% -- 2nd ATH
Gen L
TRx: 239,100 {vs 253,110; -5.54%}
NRx: 95,259 {vs 102,070; -6.67%}
L
TRx: 4,340 {vs 4,640; -6.47%}
NRx: 1,507 {vs 1,650; -8.67%}
Monthly Retail TRx Market Share: 36.06% vs 34.82% --- ATH
Monthly Retail NRx Market Share: 37.08% vs 35.44% --- ATH
Monthly Retail Refills Market Share: 35.36% vs 34.40% --- ATH
Raf,
You passed the Test, marginally though 10.5/20 :):):):)
Scripts Update for Week Ending 30/11
ATH Across the Board in TRx, NRx & Refills Numbers
V
TRx: 33,963 {vs 28,898; +17.53%} Sector +17.90% --- ATH
NRx: 14,143 {vs 11,538; +22.58%} Sector +22.35% --- ATH
Ref: 19,820 {vs 17,360; +14.17%} Sector +15.08% --- ATH
GenL
TRx: 58,596 {vs 49,564; +18.22%}
NRx: 23,139 {vs 18,934; +22.21%}
L
TRx: 1,038 {vs 926; +12.10%}
NRx: 375 {vs 306; +22.55%}
V TRx Market Share: 36.29% vs 36.40% -- 2nd ATH
V NRx Market Share: 37.56% vs 37.49% --- ATH
V Ref Market Share: 35.43% vs 35.71% -- 3rd ATH
Scripts True Comparison vs 2 Weeks ago, Week Ending 16/11
Week Ending 30/11 vs Week Ending 16/11 since Week Ending 23/11 was a Short Week
V
TRx: 33,963 {vs 32,548; +4.34%} Sector +4.07% --- ATH
NRx: 14,143 {vs 13,953; +1.36%} Sector +1.11% --- ATH
Ref: 19,820 {vs 18,595; +6.58%} Sector +6.17% --- ATH
GenL
TRx: 58,596 {vs 56,384; +3.92%}
NRx: 23,139 {vs 22,924; +0.93%}
L
TRx: 1,038 {vs 996; +4.21%}
NRx: 375 {vs 366; +2.45%}
V TRx Market Share: 36.29% vs 36.19% {would have been ATH}
V NRx Market Share: 37.56% vs 37.46% {Already ATH}
V Ref Market Share: 35.43% vs 35.29% {Would have been 2nd ATH}
Website
Just a simple recommendation if you take it into consideration;
The background of the website should be changed. The pills are too yellow, perhaps if you can use a background of vascepa pills or vascepa bottle it would be better IMO
Thanks for all the great work
National Lipid Association
National Lipid Association in the City of Roses, Portland, Ore., February 22-24, 2019, at the Hilton Downtown Portland
Don't know if this was posted before, but the NLA have REDUCE IT on their agenda (Session II): Implications of REDUCE-IT Results and Other Trials in Progress as can be seen in the below image and link
https://www.lipid.org/springclu
Scripts Update for Week Ending 23/11
Short Week due to Thanksgiving. Most doctors were off Thursday & Friday
What matters is the Market Share and V is at ATH Across the Board in Market Share
V
TRx: 28,898 {vs 32,548; -11.21%} Sector -11.72%
NRx: 11,538 {vs 13,953; -17.31%} Sector -17.36%
Ref: 17,360 {vs 18,595; -6.64%} Sector -7.73%
GenL
TRx: 49,564 {vs 56,384; -12.10%}
NRx: 18,934 {vs 22,924; -17.41%}
L
TRx: 926 {vs 996; -7.03%}
NRx: 306 {vs 366; -16.39%}
V TRx Market Share: 36.40% vs 36.19% --- ATH
V NRx Market Share: 37.49% vs 37.46% --- ATH
V Ref Market Share: 35.71% vs 35.29% --- ATH
SCRIPTS EXPECTATIONS
Tomorrow's scripts will be for week ending 23/11/2018 which is a short week.
If scripts especially NRx are good, that will be an amazing surprise, but do not puts lots of expectations and hope on tomorrow's numbers.
Below you will find the %change historically for years 2015 - 2016 & 2017 for this short week
2015
V TRx -14.03% --- Sector TRx -12.49%
V NRx -20.88% --- Sector NRx -19.75%
V Ref -8.70% --- Sector Ref -7.77%
2016
V TRx -11.31% --- Sector TRx -11.51%
V NRx -18.90% --- Sector NRx -18.80%
V Ref -6.51% --- Sector Ref -7.15%
2017
V TRx -13.72% --- Sector TRx -12.78%
V NRx -17.87% --- Sector NRx -19.27%
V Ref -11.17% --- Sector Ref -8.77%
TTE
$9/month or $72/year
Laughing before typing this :):)
It is not about the money, it's the idea and possibility of paying money and having someone like pyrr on the board and that will be one hell of a waste of money
$9/month or $72/year
BB
In AMRN filing yesterday, the below quoted is there for everyone to read:
"Based on the positive REDUCE-IT results, we have begun promoting REDUCE-IT results to healthcare professionals in the United
States based on what we believe is our continuing obligation under our First Amendment settlement to ensure that our promotion of
Vascepa remains truthful and non-misleading. We are also developing Vascepa for FDA approval of additional indications based on
REDUCE-IT."
Use of Proceeds
“We intend to use the net proceeds from this offering (1) to support the ongoing commercialization of Vascepa following REDUCE-IT results, including (i) seeking regulatory approval to expand the approved label for Vascepa based on the cardioprotective effect of Vascepa demonstrated in the REDUCE-IT study, beginning with submission of an sNDA to the FDA in early 2019, (ii) expansion of our sales force, and (iii) support of expanded commercial operations; (2) to increase commercial supply of Vascepa from third-party drug product suppliers; and (3) for general corporate purposes. We also may use a portion of the net proceeds to acquire strategic assets, although we currently have no agreements or commitments in this regard. See “Use of Proceeds.””
That is new
Maybe, just thinking out loud now, perphaps acquiring an EPA supply firm :):)
We were all expecting this, and IMO it make the balance sheet stronger and give them an edge in any partnership deal they intend to negotiate in the future
HONDO,
There you go, it was posted last week
Scripts Update for Week Ending 16/11
ATH in Numbers & Market Share for TRx & NRx – 2nd ATH in Refills
Sector reaching a total number in TRx & NRx not seen since 2015 -- > V increasing the sector’s number and reaching ATH in Market Share
V
TRx: 32,548 {vs 31,811; +2.32%} Sector +1.06% --- ATH
NRx: 13,953 {vs 12,918; +8.01%} Sector +3.99% --- ATH
Ref: 18,595 {vs 18,893; -1.58%} Sector -0.92% --- 2nd ATH
GenL
TRx: 56,384 {vs 56,087; +0.53%}
NRx: 22,924 {vs 22,529; +1.75%}
L
TRx: 996 {vs 1,091; -8.71%}
NRx: 366 {vs 368; -0.54%}
V TRx Market Share: 36.19% vs 35.75% --- ATH
V NRx Market Share: 37.46% vs 36.07% --- ATH
V Ref Market Share: 35.29% vs 35.53% --- 2nd ATH
Scripts Update for Week Ending 16/11
ATH in Numbers & Market Share for TRx & NRx – 2nd ATH in Refills
Sector reaching a total number in TRx & NRx not seen since 2015 -- > V increasing the sector’s number and reaching ATH in Market Share
V
TRx: 32,548 {vs 31,811; +2.32%} Sector +1.06% --- ATH
NRx: 13,953 {vs 12,918; +8.01%} Sector +3.99% --- ATH
Ref: 18,595 {vs 18,893; -1.58%} Sector -0.92% --- 2nd ATH
GenL
TRx: 56,384 {vs 56,087; +0.53%}
NRx: 22,924 {vs 22,529; +1.75%}
L
TRx: 996 {vs 1,091; -8.71%}
NRx: 366 {vs 368; -0.54%}
V TRx Market Share: 36.19% vs 35.75% --- ATH
V NRx Market Share: 37.46% vs 36.07% --- ATH
V Ref Market Share: 35.29% vs 35.53% --- 2nd ATH
Scripts Update for Week Ending 16/11
ATH in Numbers & Market Share for TRx & NRx – 2nd ATH in Refills
Sector reaching a total number in TRx & NRx not seen since 2015 -- > V increasing the sector’s numbers and reaching ATH in Market Share while doing that
I simply love Deepak L. Bhatt answer below regarding mineral oil in an interview posted few days back
Sorry if someone posted it before
https://www.medscape.com/viewarticle/904764?src=soc_tw_181119_mscpedt_news_pharm_aha18&faf=1
CV Risk: Can Prescription Omega-3 REDUCE-IT?
An Interview With Deepak Bhatt
Interviewer: Melissa K. Walton-Shirley, MD; Interviewee: Deepak L. Bhatt, MD, MPH
For those folks that are really skeptical, it's not a 25% but a 20% risk reduction. Does that materially change anything? With a good safety and tolerability profile, would someone say, "Oh, it's only 20%; I'm not going to use it"?
If one believes that the difference in the two arms is from the placebo arm, and if you believe that cardiovascular death was reduced in this trial, where that's an adjudicated endpoint, a blinded trial, 99.8% ascertainment of mortality... If you believe that cardiovascular death, as you should, doesn't that then mean the conclusion is mineral oil is raising cardiovascular death? If we believe that, we should stop taping. We should call the FDA and say, "Get that mineral oil off the shelf. It's killing babies and old people."
BB
Going back to numbers from start of June-2018, this happened only twice before;
Week Ending 27/07
V
TRx: 28,317 {vs 27,568; +2.72%} Sector +0.48% -- 2nd ATH
NRx: 11,249 {vs 10,749; +4.22%} Sector +1.32% -- ATH
Ref: 17,068 {vs 16,773; +1.76%} Sector -0.07% -- 2nd ATH
GenL
TRx: 52,230 {vs 52,577; -0.66%}
NRx: 20,875 {vs 20,914; -0.19%}
Week Ending 26/10
V
TRx: 30,423 {vs 30,081; +1.14%} Sector -0.41% --- 2nd ATH {ATH=30,569}
NRx: 12,567 {vs 12,430; +1.10%} Sector -0.60% --- 2nd ATH {ATH=12,852}
Ref: 17,856 {vs 17,651; +1.16%} Sector -0.28% --- ATH
GenL
TRx: 54,989 {vs 55,735; -1.34%}
NRx: 22,144 {vs 22,492; -1.55%}
Scripts Update for Week Ending 09/11
ATH Across the Board in Numbers & Market Share
V
TRx: 31,811 {vs 30,956; +2.76%} Sector +0.71% --- ATH
NRx: 12,918 {vs 12,746; +1.35%} Sector +0.34% --- ATH
Ref: 18,893 {vs 18,210; +3.75%} Sector +0.96% --- ATH
GenL
TRx: 56,087 {vs 56,433; -0.91%}
NRx: 22,529 {vs 22,624; -0.42%}
L
TRx: 1,091 {vs 973; +12.13%}
NRx: 368 {vs 325; +13.23%}
V TRx Market Share: 35.75% vs 35.03% --- ATH
V NRx Market Share: 36.07 % vs 35.71% --- ATH
V Ref Market Share: 35.53% vs 34.58% --- ATH
Thanks for the feedback JL
JL,
A quick question based on your medical experience and history.
I am following closely EVOLUS INC (EOLS), seems they are going for an approval in Q1-2019 for a new enhanced type of Botox....have u heard about the company and their product? any feedback?
Much appreciated
Circuit,
I sure don’t mind.
I have the graph ready at the office but I didn’t have time to post it. Will do that tmw hopefully
Total Monthly Retail ONLY Data October-2018
ATH Across the Board in Numbers & Market Share
This is the 1st full month after release of results on 24/09 and way before AHA addition. Just take a few seconds and imagine the huge scripts increase from here onward
Mineral Oil, AF, MH & Pyrr MY A*&%
V
TRx: 137,710 {vs 117,710; +16.99%} – Sector +12.57% --- ATH
NRx: 56,930 {vs 46,039; +23.66%} – Sector 15.32% --- ATH
Ref: 80,780 {vs 71,671; +12.71%} – Sector +10.76% --- ATH
Gen L
TRx: 253,110 {vs 229,270; +10.40%}
NRx: 102,070 {vs 91,783; +11.21%}
L
TRx: 4,640 {vs 4,320; +7.41%}
NRx: 1,650 {vs 1,488; +10.89%}
Monthly Retail TRx Market Share: 34.82% vs 33.51% --- ATH
Monthly Retail NRx Market Share: 35.44% vs 33.05% --- ATH
Monthly Retail Refills Market Share: 34.40% vs 33.81% --- ATH
Total Monthly Retail ONLY Data October-2018
ATH Across the Board in Numbers & Market Share
This is the 1st full month after release of results on 24/09 and way before AHA addition. Just take a few seconds and imagine the huge scripts increase from here onward
Mineral Oil, AF, MH & Pyrr MY A*&%
JT now next on CNBC
Another hit article by seeking alpha,
All aligned and prepared and talking about same pts that was explained, analysed and refuted by FDA in Adcom and yesterday
Their FEUD won't affect anything, let them talk as they are paid by others while in reality their will be aiming to buy cheap shares and go long
That ain't gonna happen
Those need to be investigated by the SEC, from Adam to harper and this dude, Dr my ass....
https://seekingalpha.com/article/4221035-amarins-reduce-trial-something-fishy